Medera Inc

Medera Inc. is a privately held, clinical-stage company headquartered in Irvine, California. Founded in 2014, the company employs four people and generates approximately $50 million in annual revenue. Medera focuses on developing next-generation cell and gene therapies to address difficult-to-treat and incurable diseases. Medera’s research and development efforts target a variety of cardiac, vascular, and muscular conditions. These include Heart Failure with preserved Ejection Fraction (HFpEF), Duchenne Muscular Dystrophy, and Pulmonary Hypertension. The company operates through two subsidiaries: Novoheart and Sardocor. Novoheart specializes in disease modeling and drug discovery using its proprietary mini-Heart Technology. This platform enables the creation of bioengineered human heart constructs, including the world’s first human heart-in-a-jar, to test the toxicity and efficacy of potential therapies. Sardocor focuses on the clinical development of novel therapies. It leverages Novoheart's bioengineered human tissue-based assays for disease modeling and drug discovery to expedite the regulatory approval process for next-generation cell and gene therapies. Prior to its acquisition by Medera, Novoheart was publicly traded on both the Toronto Stock Exchange and the Frankfurt Stock Exchange. For more information about Medera Inc. and its subsidiaries, please visit www.medera.bio.